A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduct...
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study “Combined Metabolic Activators Improve Cognitive...
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study “Combined Metabolic Activators Improves Cognitive...
The results of a Phase II and III studies have been published in the journal Advanced Science. COVID-19 is associated with mi...
The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study “Combined Metabolic Activators A...
ScandiBio Therapeutics announced results from the study “Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty L...